Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy

Autor: Lili Yu, Stephen G. Swisher, Xiaoshan Zhang, Li Wang, Bingliang Fang, J. Wang, Xiang Yan, Xingxiang Pu, Don L. Gibbons, Ismail M. Meraz, Ran Zhang, Reza J. Mehran, Jack A. Roth, Shuhong Wu

Publikováno v: OncoImmunology, Vol 7, Iss 1 (2018)

Anti-PD-1 and anti-PD-L1 immunotherapy has provided a new therapeutic opportunity for treatment of advanced-stage non-small cell lung cancer (NSCLC). However, overall objective response rates are approximately 15%-25% in all NSCLC patients who receiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdfbbe96ac51c7cc7fa83626b35eff98
https://doaj.org/article/e4976eb5eddb411fa030ad81eac6165b

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.

Autor: Yan X; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China., Wang L; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang R; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pu X; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wu S; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yu L; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meraz IM; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang X; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang JF; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gibbons DL; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mehran RJ; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Swisher SG; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fang B; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2017 Oct 31; Vol. 7 (1), pp. e1376156. Date of Electronic Publication: 2017 Oct 31 (Print Publication: 2017).